In vitro and in vivo characterization of [⁶⁴Cu][Cu(elesclomol)] as a novel theranostic agent for hypoxic solid tumors.

ABSTRACT:

Purpose

Hypoxic tumors are associated with therapy resistance and poor cancer prognosis, but methods to detect and counter tumor hypoxia remain insufficient. Our purpose was to investigate ⁶⁴Cu(II)-elesclomol ([⁶⁴Cu][Cu(ES)]) as a novel theranostic agent for hypoxic tumors, by implementing an improved production method and assessing its therapeutic and diagnostic potential compared to the established Cu-64 radiopharmaceuticals [⁶⁴Cu]CuCl₂ and [diacetyl-bis(N4-methylthiosemicarbazone) [⁶⁴Cu][Cu(ATSM)].

Methods

Cu-64 was produced using a biomedical cyclotron at 12 MeV with the reaction ⁶⁴Ni(p,n)⁶⁴Cu, followed by synthesis of [⁶⁴Cu]CuCl₂, [⁶⁴Cu][Cu(ATSM)], and [^64<

SUBMITTER: Liu T 

PROVIDER: S-EPMC10547809 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature